Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes-Reference-Cited by-同舟云学术

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Published:2020-08-03 Issue:10 Volume:26 Page:1549-1556
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Bernard Elsa^ORCID,Nannya Yasuhito,Hasserjian Robert P.,Devlin Sean M.,Tuechler Heinz^ORCID,Medina-Martinez Juan S.,Yoshizato Tetsuichi^ORCID,Shiozawa Yusuke,Saiki Ryunosuke,Malcovati Luca,Levine Max F.^ORCID,Arango Juan E.,Zhou Yangyu,Solé Francesc,Cargo Catherine A.,Haase Detlef,Creignou Maria,Germing Ulrich,Zhang Yanming,Gundem Gunes,Sarian Araxe,van de Loosdrecht Arjan A.,Jädersten Martin,Tobiasson Magnus,Kosmider Olivier,Follo Matilde Y.^ORCID,Thol Felicitas,Pinheiro Ronald F.,Santini Valeria,Kotsianidis Ioannis,Boultwood Jacqueline^ORCID,Santos Fabio P. S.,Schanz Julie,Kasahara Senji,Ishikawa Takayuki,Tsurumi Hisashi,Takaori-Kondo Akifumi^ORCID,Kiguchi Toru,Polprasert Chantana,Bennett John M.,Klimek Virginia M.,Savona Michael R.^ORCID,Belickova Monika^ORCID,Ganster Christina^ORCID,Palomo Laura,Sanz Guillermo^ORCID,Ades Lionel,Della Porta Matteo Giovanni,Elias Harold K.,Smith Alexandra G.,Werner Yesenia,Patel Minal,Viale Agnès,Vanness Katelynd,Neuberg Donna S.^ORCID,Stevenson Kristen E.,Menghrajani Kamal,Bolton Kelly L.,Fenaux Pierre,Pellagatti Andrea,Platzbecker Uwe,Heuser Michael^ORCID,Valent Peter,Chiba Shigeru,Miyazaki Yasushi,Finelli Carlo,Voso Maria Teresa^ORCID,Shih Lee-Yung,Fontenay Michaela^ORCID,Jansen Joop H.,Cervera José,Atsuta Yoshiko,Gattermann Norbert,Ebert Benjamin L.^ORCID,Bejar Rafael^ORCID,Greenberg Peter L.,Cazzola Mario^ORCID,Hellström-Lindberg Eva,Ogawa Seishi^ORCID,Papaemmanuil Elli^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-020-1008-z.pdf

Reference49 articles.

1. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).

2. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

3. Haase, D. et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia 33, 1747–1758 (2019).

4. Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496–2506 (2011).

5. Kitagawa, M., Yoshida, S., Kuwata, T., Tanizawa, T. & Kamiyama, R. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. Am. J. Pathol. 145, 338–344 (1994).

Cited by 362 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics and genomics of acute myeloid leukemia;Best Practice & Research Clinical Haematology;2024-03

2. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia;Blood Advances;2024-02-13

3. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML;Blood Advances;2024-02-13

4. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study;The Lancet Haematology;2024-02

5. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms;Modern Pathology;2024-02